Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


1 Acta Haematol
3 Am J Hematol
5 Ann Hematol
1 Ann Oncol
9 Blood
4 Bone Marrow Transplant
1 Eur J Haematol
1 Exp Cell Res
2 Exp Hematol
1 Int J Hematol
2 J Clin Oncol
3 J Pediatr Hematol Oncol
1 J Virol
8 Leuk Lymphoma
1 Leuk Res
1 N Engl J Med
1 Oncol Rep
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Haematol

  1. PETERLIN P, Garnier A, Le Bourgeois A, Jullien M, et al
    Dramatic recovery after etoposide phosphate infusion for hemophagocytic lymphohistiocytosis/macrophage activation syndrome following treatment with tisagenlecleucel in a young patient with relapsed acute lymphoblastic leukemia: a case report.
    Acta Haematol. 2022 Jun 20. pii: 000525576. doi: 10.1159/000525576.
    PubMed         Abstract available

    Am J Hematol

  2. DHOPESHWARKAR N, Yang W, Hennessy S, Rhodes JM, et al
    Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: a population-based cohort study.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26632.

  3. JABBOUR EJ, Short NJ, Jain N, Jammal N, et al
    Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10(-4) and Higher.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26634.
    PubMed         Abstract available

  4. BARON F, Labopin M, Tischer J, Ciceri F, et al
    Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients >/=55 years of age.
    Am J Hematol. 2022 Jun 13. doi: 10.1002/ajh.26627.
    PubMed         Abstract available

    Ann Hematol

  5. SHIMONY S, Canaani J, Kugler E, Nachmias B, et al
    Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
    Ann Hematol. 2022 Jun 24. pii: 10.1007/s00277-022-04895.
    PubMed         Abstract available

  6. WOLACH O, Frisch A, Shargian L, Yeshurun M, et al
    Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.
    Ann Hematol. 2022 Jun 23. pii: 10.1007/s00277-022-04883.
    PubMed         Abstract available

  7. KATHPALIA M, Mishra P, Bajpai R, Bhurani D, et al
    Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2022 Jun 21. pii: 10.1007/s00277-022-04880.
    PubMed         Abstract available

  8. WU X, Cheng L, Liu X, Sun Y, et al
    Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.
    Ann Hematol. 2022;101:1493-1498.
    PubMed         Abstract available

  9. HIRANO M, Tamba M, Inoue N, Ikegami M, et al
    Durable response of therapy-related MDS/AML with concomitant Waldenstrom's macroglobulinemia treated with venetoclax and azacitidine.
    Ann Hematol. 2022;101:1587-1589.

    Ann Oncol

  10. GEYER CE, Sikov WM, Loibl S
    Reply to the Letter to the Editor "Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer" by A. Okines and N. Turner.
    Ann Oncol. 2022 Apr 4. pii: S0923-7534(22)00671.


  11. MURDOCK HM, Kim HT, Denlinger N, Vachhani P, et al
    Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.
    Blood. 2022;139:3546-3557.
    PubMed         Abstract available

  12. PASSET M, Kim R, Gachet S, Sigaux F, et al
    Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.
    Blood. 2022;139:3505-3518.
    PubMed         Abstract available

  13. YEUNG DT, Shanmuganathan N, Hughes TP
    Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
    Blood. 2022;139:3474-3479.
    PubMed         Abstract available

  14. Genetics and outcome in older AML transplant.
    Blood. 2022;139:3559.

  15. FREEMAN SD, Valk P
    Transplant in older adults with AML: genomic wheat and chaff.
    Blood. 2022;139:3459-3461.

    Why B(-)other? About the gap of unknowns in ALL.
    Blood. 2022;139:3455-3457.

  17. TANAKA A, Nakano TA, Nomura M, Yamazaki H, et al
    Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
    Blood. 2022 Jun 16. pii: 485590. doi: 10.1182/blood.2021015325.
    PubMed         Abstract available

  18. Al-Sawaf O, Lilienweiss E, Bahlo J, et al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood. 2020;135(11):866-870.
    Blood. 2022;139:3669.

  19. QIU L, Quesada AE
    Plasma cell leukemia with small cell morphology.
    Blood. 2022;139:3667.

    Bone Marrow Transplant

  20. OHMOTO A, Fuji S, Shultes KC, Savani BN, et al
    Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.
    Bone Marrow Transplant. 2022;57:874-880.
    PubMed         Abstract available

  21. KEVLICIUS L, Cepulyte R, Vasilevska D, Griskevicius L, et al
    Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies.
    Bone Marrow Transplant. 2022;57:1034-1037.

  22. MAAKARON JE, Zhang MJ, Chen K, Abhyankar S, et al
    Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.
    Bone Marrow Transplant. 2022;57:911-917.
    PubMed         Abstract available

  23. ONIDA F, Sbianchi G, Radujkovic A, Sockel K, et al
    Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.
    Bone Marrow Transplant. 2022;57:896-902.
    PubMed         Abstract available

    Eur J Haematol

  24. TRACY SI, Cao Q, Bachan B, Meredith M, et al
    Ph-like gene alterations and complex chromosomal abnormalities are frequent in patients with acute lymphoblastic leukemia experiencing relapse after allogeneic hematopoietic cell transplantation.
    Eur J Haematol. 2022 Jun 14. doi: 10.1111/ejh.13814.

    Exp Cell Res

  25. CHEN CW, Huang NK, Lee YL, Fan CK, et al
    Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid differentiation that sensitizes BCR-ABL-positive cells to imatinib.
    Exp Cell Res. 2022;417:113219.
    PubMed         Abstract available

    Exp Hematol

  26. SOMMERKAMP P, Brown JA, Haltalli MLR, Mercier FE, et al
    m(6)A RNA modifications: Key regulators of normal and malignant hematopoiesis.
    Exp Hematol. 2022;111:25-31.
    PubMed         Abstract available

  27. UPADHYAY P, Beales J, Shah NM, Gruszczynska A, et al
    Recurrent transcriptional responses in AML and MDS patients treated with decitabine.
    Exp Hematol. 2022;111:50-65.
    PubMed         Abstract available

    Int J Hematol

  28. CAO XY, Li JJ, Lu PH, Liu KY, et al
    Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2022 Jun 23. pii: 10.1007/s12185-022-03398.
    PubMed         Abstract available

    J Clin Oncol

  29. ARMENIAN SH, Chen Y, Hageman L, Wu J, et al
    Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study.
    J Clin Oncol. 2022 Jun 22:JCO2102829. doi: 10.1200/JCO.21.02829.
    PubMed         Abstract available

  30. MOORMAN AV, Antony G, Wade R, Butler ER, et al
    Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial.
    J Clin Oncol. 2022 Jun 17:JCO2200245. doi: 10.1200/JCO.22.00245.
    PubMed         Abstract available

    J Pediatr Hematol Oncol

  31. Clinical Significance of MicroRNA-29a and MicroRNA-100 Gene Expression in Pediatric Acute Myeloid Leukemia: Erratum.
    J Pediatr Hematol Oncol. 2022;44:272.

  32. AGRAWAL R, Sahay A, Patil A, Ramadwar M, et al
    Phyllodes Tumor as a Secondary Neoplasm in Survivors of Childhood Cancer: A Tertiary Care Cancer Centre Experience.
    J Pediatr Hematol Oncol. 2022;44:264-267.
    PubMed         Abstract available

  33. DADI G, Jacoby E, Toren A, Bielorai B, et al
    Bortezomib-based Anthracycline-free Induction for Pediatric Relapsed ALL as a Bridge to Immunotherapy.
    J Pediatr Hematol Oncol. 2022;44:e896-e900.
    PubMed         Abstract available

    J Virol

  34. TURY S, Giovannini D, Ivanova S, Touhami J, et al
    Identification of Copper Transporter 1 as a Receptor for Feline Endogenous Retrovirus ERV-DC14.
    J Virol. 2022;96:e0022922.
    PubMed         Abstract available

    Leuk Lymphoma

  35. KOHN M, Alsuliman T, Lamure S, Cheminant M, et al
    Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086249.

  36. TEDJASEPUTRA A, Kuzich JA, Thiagarajah N, Teh TC, et al
    Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic.
    Leuk Lymphoma. 2022 Jun 21:1-4. doi: 10.1080/10428194.2022.2087065.

  37. NGO D, Otoukesh S, Stein AS, Forman S, et al
    The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Jun 21:1-3. doi: 10.1080/10428194.2022.2090555.

  38. SERPENTI F, Sciume M, Galassi G, Saporiti G, et al
    Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse.
    Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.

  39. ZONG L, Xie J, Kong J, Bao X, et al
    Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Jun 23:1-3. doi: 10.1080/10428194.2022.2064984.

  40. DHAKAL P, Joshi U, Lyden E, Pyakuryal A, et al
    Association of insurance types and outcomes in acute promyelocytic leukemia.
    Leuk Lymphoma. 2022 Jun 23:1-9. doi: 10.1080/10428194.2022.2090554.
    PubMed         Abstract available

  41. RAA DGT, van der Straten L, van Gelder M, Kersting S, et al
    Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
    Leuk Lymphoma. 2022 Jun 23:1-14. doi: 10.1080/10428194.2022.2084731.
    PubMed         Abstract available

  42. XU GF, Liu LM, Wang M, Zhang ZB, et al
    Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China.
    Leuk Lymphoma. 2022 Jun 24:1-11. doi: 10.1080/10428194.2022.2090550.
    PubMed         Abstract available

    Leuk Res

  43. OTHMAN T, Moskoff BN, Ho G, Tenold ME, et al
    Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
    Leuk Res. 2022;119:106885.
    PubMed         Abstract available

    N Engl J Med

  44. FOA R, Chiaretti S
    Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    N Engl J Med. 2022;386:2399-2411.

    Oncol Rep

  45. KAEHLER M, Litterst M, Kolarova J, Bohm R, et al
    Genomewide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitorresistant CML cells.
    Oncol Rep. 2022;48.
    PubMed         Abstract available

    PLoS One

  46. VIJAYVARGIYA P, Feri A, Mairey M, Rouillon C, et al
    Metagenomic shotgun sequencing of blood to identify bacteria and viruses in leukemic febrile neutropenia.
    PLoS One. 2022;17:e0269405.
    PubMed         Abstract available

  47. LIISBORG C, Skov V, Kjaer L, Hasselbalch HC, et al
    Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers.
    PLoS One. 2022;17:e0269960.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.